Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
53230-10-7
Molecular formula
C17H16F6N2O
Molecular weight
378.31 g/mol
Drug class
Antimalarial
Mechanism of action
Acts as a blood schizonticide against erythrocytic stages of Plasmodium species. Its precise mechanism of action is not known.
Indications / reported uses
Treatment of mild to moderate acute malaria caused by mefloquine-susceptible Plasmodium falciparum or Plasmodium vivax
Prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria, including chloroquine-resistant P. falciparum
Drug class, mechanism of action and general use cases
Drug class
Antimalarial
General use cases
Malaria, Falciparum
Malaria, Vivax
mild to moderate acute malaria caused by mefloquine-susceptible strains of P
P
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Assessment scope
Project-specific PDE/ADE and OEL/OEB support
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mefloquine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mefloquine Permitted Daily Exposure (PDE) report (the Mefloquine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mefloquine Occupational Exposure Limit (OEL) report (the Mefloquine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.